Indication

Chronic Lymphocytic Leukemia With Unmutated IGHV Gene

1 clinical trial

2 products

Clinical trial

Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Product

Product

Pneumococcal Polyvalent Vaccine